Mitochondrial Inhibitor Atovaquone Increases Tumor Oxygenation and Inhibits Hypoxic Gene Expression in Patients with Non-Small Cell Lung Cancer

PURPOSE: Tumor hypoxia fuels an aggressive tumor phenotype and confers resistance to anti-cancer treatments. We conducted a clinical trial to determine whether the antimalarial drug atovaquone, a known mitochondrial inhibitor, reduces hypoxia in non-small cell lung cancer (NSCLC). PATIENTS AND METHO...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
الحاوية / القاعدة:Clin Cancer Res
المؤلفون الرئيسيون: Skwarski, Michael, McGowan, Daniel R, Belcher, Elizabeth, Di Chiara, Francesco, Stavroulias, Dionisios, McCole, Mark, Derham, Jennifer L, Chu, Kwun-Ye, Teoh, Eugene, Chauhan, Jagat, O’Reilly, Dawn, Harris, Benjamin HL, Macklin, Philip S, Bull, Joshua A, Green, Marcus, Rodriguez-Berriguete, Gonzalo, Prevo, Remko, Folkes, Lisa K, Campo, Leticia, Ferencz, Petra, Croal, Paula L, Flight, Helen, Qi, Cathy, Holmes, Jane, O’Connor, James PB, Gleeson, Fergus V, McKenna, W Gillies, Harris, Adrian L, Bulte, Daniel, Buffa, Francesca M, Macpherson, Ruth E, Higgins, Geoff S
التنسيق: Artigo
اللغة:Inglês
منشور في: 2021
الموضوعات:
Article
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC7611473/
https://ncbi.nlm.nih.gov/pubmed/33597271
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-20-4128
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة